Sign In
Last checked at 
1 Apr 2009 07:00
TIME.L
Timestrip plc
(the "Company")
New Product Launch and NHS order
The Company is pleased to announce the launch of a new product range - TimestripMedical - targeting healthcare providers with a number of different time and temperature based solutions to existing problems and issues in the healthcare environment.
The first product in the range, TimestripIV, has been designed to help hospitals comply with existing policy directives that stipulate the need to change Peripheral Intravenous Cannulae (PVCs) every 72 hours. Up to 60% of cases of blood infections known as MRSA Bacteraemia are caused by PVC's and the cost of treating MRSA is estimated at £1 billion per annum, according to the National Audit Office.
The Company is delighted to announce that it has received high levels of interest for this product from the UK's National Health Service, culminating in today's launch of a six months detailed assessment of TimestripIV by the Whittington Hospital in London.
The Whittington has placed an order to purchase sufficient quantities of TimestripIV products to enable it to use TimestripIV in conjunction with PVCs that are used in the Hospital over the next six months. The Whittington has also undertaken to produce and publish studies and surveys involving practitioners and patients to evaluate the effectiveness of TimestripIV within the Hospital's infection control policy.
Paul Freedman, Joint CEO Timestrip Plc: " We are delighted to announce this significant move into the healthcare market. TimestripIV can play an important role in the infection control policies of hospitals, helping to increase patient safety in a truly cost effective way. MRSA Bacteraemia is a global issue and we are delighted to have started working with the NHS on a product line that we believe has worldwide relevance. Other products in the TimestripMedical range will be announced in due course."
Deborah Wheeler, Director of Nursing & Clinical Development Whittington Hospital NHS Trust: "We are very impressed by the potential of TimestripIV to assist in the monitoring of compliance with IV peripheral line replacement and see it as an important innovation for the Whittington to be introducing for the first time in the NHS. The Whittington places a high priority on patient protection and satisfaction and we believe that TimestripIV represents a unique opportunity to involve patients in their own care and increase confidence in the infection control policies that we have in place."
For more information please contact:
Paul Freedman, Joint CEO, Timestrip Plc 01462 440700
Geoff Nash, FinnCap, NOMAD 020 7600 1658
Follow the stocks
